Neurogene (NGNE) said Monday that the US Food and Drug Administration has allowed the company to continue an early-stage trial using a lower dose of NGN-401, the company's intended gene therapy for Rett syndrome, a rare genetic neurological disorder.
The company said it had paused the higher-dose cohort of the study following a previously disclosed emerging treatment-related serious adverse event in a trial participant. It also said it does not plan to enroll any more participants at the higher-dose level.
So far, the company said it had not received reports of other treatment-related serious adverse events in the trial. However, it said that it no longer expects to complete enrollment of participants in the low-dose cohort in Q4.
Shares of the company fell more than 18% in premarket activity.
Price: 28.00, Change: -6.51, Percent Change: -18.88
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。